Opthea (NASDAQ:OPT - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Opthea to post earnings of ($0.43) per share for the quarter.
Opthea Price Performance
NASDAQ:OPT traded up $0.03 on Friday, reaching $5.02. The stock had a trading volume of 11,765 shares, compared to its average volume of 35,566. Opthea has a 12-month low of $1.79 and a 12-month high of $6.30. The firm's fifty day moving average is $4.33 and its two-hundred day moving average is $3.87.
Analyst Upgrades and Downgrades
OPT has been the subject of several analyst reports. Canaccord Genuity Group upgraded Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Opthea in a research note on Wednesday, January 29th.
Check Out Our Latest Analysis on Opthea
Opthea Company Profile
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
